Where Lies the Competitiveness of China's New Drugs for Central Nervous System?
The Global Challenges and Opportunities of the R&D of New Drugs for Central Nervous System
October 18, 2024
by Prof. Zhang
Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives
Artemisinin is a sesquiterpene lactone compound with a peroxide group structure extracted from the leaves of Artemisia annua, a plant belonging to the Asteraceae family.
July 19, 2024
by Xiaomichong
A Brief Introduction to Drug Treatment and New Drug Development for Chronic Cough
Chronic cough (CC) is a common disease with a prevalence rate of up to 12%, significantly affecting the quality of life of patients.
July 15, 2024
by Xiaomichong
Research Progress on the Mechanism of Hypertension and New Drug Development
October 8th of every year is National Hypertension Day. Hypertension is a cardiovascular syndrome with elevated arterial pressure as its main clinical manifestation.
July 8, 2024
by Xiaomichong
Eurofins CDMO Expands Drug Product Capabilities in Canada
Eurofins CDMO has expanded its existing drug product operation capabilities with the early 2020 completion of its new drug product development and cGMP manufacturing facility, located in Mississauga, Canada.
November 6, 2020
by contractpharma
Hengrui's Application for New Class 1.1 Drug Hetrombopag Ethanolamine Tablets was Accepted by CDE
On June 18, the marketing application of Hengrui's new class 1.1 drug Hetrombopag ethanolamine tablets was accepted by CDE.
June 19, 2020
by PharmaSources/Dopine
FDA new drug approvals down 16 percent in 2019, impacting outsourcing
A new report has found that in 2019 the FDA approved 119 new drugs and biologics, but that this is down from 137 in 2018, impacting contract manufacturing organisations.
May 14, 2020
by europeanpharmaceuticalreview
Harvest in 2019 year-end with the Marketing of Multiple Generic Drugs
The NMPA is also “sprinting” as the year is coming to an end.
January 7, 2020
by PharmaSources/Caicai
Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets ...
December 11, 2019
by pharmaceutical-business-review
Shanghai Green Valley’s Class 1 New Drug for Alzheimer’s Disease Conditionally Approved for Marketing and Already Having the Registration Approval!
The National Medical Products Administration of China (NMPA) released on its website yesterday (Nov. 2, 2019) some big news that shocks the industry.
November 14, 2019
by PharmaSources/Caicai
UF researchers focus on new drug candidate Apratoxin S4 to treat vision loss
Researchers from the University of Florida (UF) College of Pharmacy have announced a partnership to focus on a new drug candidate Apratoxin S4 as a new method to prevent or treat vision loss.
August 12, 2019
by pharmaceutical-technology
Submission and acceptance of application for the production of new drug for Yisaipu(R)aqueous injection solution
3SBio Inc. (01530.HK), a leading biopharmaceutical company in the PRC, announces today that an application for the production of new drug has been submitted to the National Medical Products Administration for ...
August 6, 2019
by prnasia